Phase I dose escalation study of MB311 in cancer patients

Trial Profile

Phase I dose escalation study of MB311 in cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs MB 311 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Meridian Biopharmaceuticals
  • Most Recent Events

    • 21 Mar 2016 Results published in company's website.
    • 21 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top